TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02462928
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab intravitreal injection.
Study: NCT00261612
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00261612
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00261612
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00244127
Drug: Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00175955
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04169347
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 week cycles
Study: NCT03478774
Drug: oxygen 0.25l/min
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25l/min of oxygen via an endotracheal tube
Study: NCT02788162
Drug: Coppertone (BAY 987517)
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - X71-144)
Study: NCT02101112
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00000506
Drug: fenfluramine
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000506
Drug: phentermine
Normalized name: Phentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02994433
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
Study: NCT02800889
Drug: Pixantrone
Normalized name: Pixantrone
DrugBank: Pixantrone (DB06193)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pixantrone
Study: NCT04236141
Drug: Polatuzumab Vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
Study: NCT04236141
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 90 mg/m2 Bendamustine (IV infusion) on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
Study: NCT04236141
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
Study: NCT00060554
Drug: fondaparinux sodium
Normalized name: Fondaparinux Sodium
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00449397
Drug: Quetiapine Fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01563614
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
Study: NCT01563614
Drug: Liposomal cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
Study: NCT03895203
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study: NCT03895203
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab will be administered according to the labeling recommendations.
Study: NCT03025698
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily
Study: NCT03025698
Drug: hATG
Normalized name: hATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)
Study: NCT03025698
Drug: CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day
Study: NCT00061958
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01221272
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * One 500 mg tablet in the evening on Day 1 of the period~* One 500 mg tablet, twice daily on Days 2-3 of the period~* Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)
Study: NCT01221272
Drug: Placebo to match ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to match ranolazine administered in the same form and frequency as the active drug.
Study: NCT00257166
Drug: Ziprasidone oral capsules
Normalized name: ziprasidone Oral Capsule
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
Study: NCT00829049
Drug: Tazarotene Cream 0.1%
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 pea-size amount, QD x 16 weeks
Study: NCT03675282
Drug: (11C)PE2I
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
Study: NCT03675282
Drug: Ioflupane
Normalized name: ioflupane
DrugBank: Ioflupane I-123 (DB08824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
Study: NCT00883259
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 850 mg twice daily
Study: NCT00829049
Drug: Adapalene
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 pea-size amount, QD x 16 weeks
Study: NCT01463670
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
Study: NCT03181867
Drug: 18F-DCFPyL
Normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IV dose of 18F-DCFPyL by bolus injection. The maximum amount of injected active drug will be less than 4.02 mcg. The target administered activity will be 8 mCi.
Study: NCT03181867
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 2 may receive a one-time 18F-FDG PET/CT after a positive 18F-DCPyL PET/CT. 18F FDG PET/CT imaging may be performed per clinical standard of care. FDG is administered at a dose of 10mCi intravenously. A whole-body PET/CT will be performed beginning post 18F FDG injection.
Study: NCT03181867
Drug: PSMA-11
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For up to 10 eligible patients from either cohort 1 or 2, an optional salivary gland blocking study may be performed in which a salivary gland is cannulated and injected with unlabeled DCFPyL or PSMA-11.
Study: NCT00000225
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02088112
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib QD
Study: NCT02418559
Drug: JNJ-63623872 (300 mg)
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
Study: NCT02418559
Drug: JNJ-63623872 (600 mg)
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-63623872 600 mg (2\*300 mg) tablet orally once on Day 1 under fasted conditions.
Study: NCT02418559
Drug: JNJ-63623872 (1200 mg)
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-63623872 1200 mg (4\*300 mg) tablet orally once on Day 1 under fasted conditions.
Study: NCT00097084
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00097084
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00097084
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01374906
Drug: pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pasireotide long-acting was administered as an intra-muscular depot intragluteal injection once every 28 days (±2 days). Patients were administered pasireotide long-acting 10 mg or 30 mg for four months, followed by either continuation of the starting dose, or dose up-titration (if mUFC was still \>1.5xULN unless titration was precluded by safety reasons).
Study: NCT01374906
Drug: SOM230 LAR 30 mg
Normalized name: pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.
Study: NCT01374906
Drug: SOM230 LAR 10 mg
Normalized name: pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
Study: NCT00295620
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg tablet daily
Study: NCT04600817
Drug: TJ107
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: QW8
Study: NCT03528967
Drug: Enoxaparin 40 mg / 0.4 mL Prefilled Syringe
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01999322
Drug: Faster-acting insulin aspart
Normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
Study: NCT01999322
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
Study: NCT03605550
Drug: PTC596
Normalized name: Bmi1 inhibitor ptc596
DrugBank: Unesbulin (DB18080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT00275236
Drug: Rotigotine
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00733850
Drug: Kanglaite Injection plus gemcitabine
Normalized name: gemcitabine Injection
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous repeating dose
Study: NCT00733850
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous repeating dose
Study: NCT01732094
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards
Study: NCT01732094
Drug: Corifollitropin alfa 150μg
Normalized name: peginterferon alfa-2b
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin
Study: NCT01425216
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
Study: NCT02414490
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
Study: NCT04351061
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide 500 mg by mouth twice per day for 7 consecutive days.
Study: NCT00951899
Drug: Colesevelam
Normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
Study: NCT00951899
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
Study: NCT02046369
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone flexibly dosed 20-80 mg once daily
Study: NCT02015299
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one tablet linagliptin 5 mg/day for 26 weeks
Study: NCT01123980
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
Study: NCT01123980
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day.
Study: NCT01123980
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day.
Study: NCT01123980
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
Study: NCT01727700
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once-daily, tablet
Study: NCT04344288
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)
Study: NCT05065658
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous posaconazole prophylaxis
Study: NCT03608072
Drug: BI 690517
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sequential dose groups
Study: NCT00583349
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abraxane is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Intravesically administered, dose escalation, 6 weekly instillations
Study: NCT00555399
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days.
Study: NCT00555399
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I/Arm 1: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m\^2/day PO x 21 days; Level -I = 100 mg/m\^2/day PO x 21 days; Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.
Study: NCT00555399
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days.
Study: NCT03827460
Drug: Intravenous Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.
Study: NCT03425331
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
Study: NCT03425331
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
Study: NCT01772472
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 mg/kg intravenously every 3 weeks, 14 cycles
Study: NCT01772472
Drug: trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3.6 mg/kg intravenously every 3 weeks, 14 cycles
Study: NCT02810704
Drug: Enteric Coated Aspirin
Normalized name: Equaline Enteric Coated Aspirin 81mg Tablet
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02810704
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02810704
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00051532
Drug: Seocalcitol
Normalized name: Seocalcitol
DrugBank: Seocalcitol (DB04258)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01481441
Drug: SonoVue
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
Study: NCT03276832
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Applied cutaneously
Study: NCT05420350
Drug: Lamotrigine and Bupropion
Normalized name: bupropion and dextromethorphan
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine-oral pill taken once or twice a day with varying dosage per study timeline Bupropion-oral pill 100mg taken twice a day
Study: NCT03822897
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
Study: NCT02138799
Drug: enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT02138799
Drug: rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00095875
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00095875
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00095875
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00971165
Drug: losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral losartan up to 100 mg daily fo 18 months
Study: NCT01355484
Drug: GTx-024
Normalized name: toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subjects will be randomized to receive GTx-024 for the full duration of the trial.
Study: NCT01280565
Drug: Masitinib
Normalized name: masitinib
DrugBank: Masitinib (DB11526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib 7.5 mg/kg/day